Cybin is a life sciences company focused on mushroom derived medicines
Location: Canada, Ontario, Toronto
Total raised: $150M
Investors 5
| Date | Name | Website |
| - | JLS Fund | jls.fund |
| - | Ambria Cap... | ambriacap.... |
| - | Noetic Fun... | noeticfund... |
| - | Synaptic V... | synaptic.v... |
| - | Subversive | subversive... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 21.03.2024 | - | $150M | - |
Mentions in press and media 11
| Date | Title | Description |
| 21.03.2024 | Cybin Raises $150M to Advance Psychedelic Therapy for Depression | What You Should Know: – Cybin Inc. (NYSE American: CYBN), a company developing next-generation psychedelic therapies for mental health, has secured $150M in a private placement of common shares led by Deep Track Capital and included partici... |
| 28.08.2023 | Cybin to Buy Small Pharma | Cybin Inc. (NYSE American:CYBN) (NEO:CYBN), a clinical-stage biopharmaceutical company developing new and innovative psychedelic-based treatment options, acquired Small Pharma Inc. (TSXV:DMT) (OTCQB:DMTTF), a U.K.-based biotechnology compan... |
| 09.01.2023 | Cybin Outlines Upcoming Priorities and Milestones for its Clinical Development Programs | Cybin, a biopharmaceutical company focused on progressing Psychedelics to Therapeutics outlined its upcoming priorities and near-term milestones that support the development of its CYB003 and CYB004 clinical programs aimed at addressing mul... |
| 04.10.2022 | ROTH Capital Partners to Host Inaugural Healthcare Opportunities Conference on October 6th at the Yale Club in New York City | Event to feature company presentations and one-on-one meetings between institutional investors and senior management from select Healthcare companies in Biotechnology, Pharmaceuticals, Medical Technologies, Oncology and Mental Health Therap... |
| 08.11.2021 | Cybin Announces Positive CYB003 Data Demonstrating Significant Advantages Over Oral Psilocybin for Treatment of Mental Health | Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“Cybin” or the “Company”), a biopharmaceutical company focused on progressing “Psychedelics to TherapeuticsTM”, today announced positive CYB003 pre-clinical findings that demonstrate multiple adva... |
| 22.03.2021 | Catalent Signs Drug Development Agreement with Cybin Inc for its Fast-Dissolve Formulation of Novel, Deuterated Tryptamine (CYB003) | Cybin logo The Zydis platform is an ideal technology to leverage for this type of drug formulation, as pre-gastric absorption is crucial for efficacy SOMERSET, N.J. (PRWEB) March 22, 2021 Catalent, the leading global provider of advanced de... |
| 15.03.2021 | Cybin to Present at the M Vest and Maxim Group 2021 Emerging Growth Virtual Conference | TORONTO--(BUSINESS WIRE)--Mar 15, 2021-- Cybin Inc. ( NEO:CYBN ) (OTCQB:CLXPF) (“ Cybin ” or the “ Company ”), a biotechnology company focused on progressing psychedelic therapeutics, today announced that Doug Drysdale, Chief Executive Offi... |
| 12.02.2020 | Cybin Corp Announces Partnership with the Toronto Centre for Psychedelic Science | TORONTO–(BUSINESS WIRE)–February 12, 2020– Cybin, Canada’s premier medicinal mushroom life sciences company with a core focus on advancing psilocybin research and intellectual property is pleased to announce a strategic partnership with the... |
| - | Cybin Progresses Two Psychedelic Investigational New Drug (“IND”) Candidates and Announces Completion of Its 20th Pre-Clinical Study | TORONTO--(BUSINESS WIRE)--Mar 17, 2021-- Cybin Inc. ( NEO:CYBN ) (OTCQB:CLXPF) (“ Cybin ” or the “ Company ”), a biotechnology company focused on progressing psychedelic therapeutics, today announced that it has completed its 20 th pre-clin... |
| - | Healthcare VC firms that backed the COVID shot and cancer treatments are now placing bets on psychedelics | Psilocybin mushrooms on a mossy log. jackfoto/iStock/Getty Images Plus This story is available exclusively to Insider subscribers. Become an Insider and start reading now. Companies developing psychedelics-based drugs need lots of cash in o... |
Show more